SELLAS Life Sciences (SLS) Common Equity (2019 - 2024)
Historic Common Equity for SELLAS Life Sciences (SLS) over the last 9 years, with Q3 2024 value amounting to $15.9 million.
- SELLAS Life Sciences' Common Equity rose 51526.0% to $15.9 million in Q3 2024 from the same period last year, while for Sep 2024 it was $15.9 million, marking a year-over-year increase of 51526.0%. This contributed to the annual value of -$8.0 million for FY2023, which is 26441.97% down from last year.
- According to the latest figures from Q3 2024, SELLAS Life Sciences' Common Equity is $15.9 million, which was up 51526.0% from $2.9 million recorded in Q2 2024.
- SELLAS Life Sciences' 5-year Common Equity high stood at $33.4 million for Q2 2021, and its period low was -$8.0 million during Q4 2023.
- Its 5-year average for Common Equity is $12.2 million, with a median of $9.7 million in 2024.
- Its Common Equity has fluctuated over the past 5 years, first surged by 78329.37% in 2021, then plummeted by 26441.97% in 2023.
- Over the past 5 years, SELLAS Life Sciences' Common Equity (Quarter) stood at $28.0 million in 2020, then dropped by 27.23% to $20.3 million in 2021, then plummeted by 76.16% to $4.9 million in 2022, then tumbled by 264.42% to -$8.0 million in 2023, then skyrocketed by 299.25% to $15.9 million in 2024.
- Its Common Equity stands at $15.9 million for Q3 2024, versus $2.9 million for Q2 2024 and $9.7 million for Q1 2024.